CSII - Cardiovascular Systems, Inc.
| Previous Close | 39.41 |
| Open | 39.52 |
| Bid | 38.20 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 39.01 - 40.16 |
| 52 Week Range | 20.89 - 42.64 |
| Volume | 426,016 |
| Avg. Volume | 503,901 |
| Market Cap | 1.377B |
| Beta (3Y Monthly) | 1.86 |
| PE Ratio (TTM) | 806.94 |
| EPS (TTM) | 0.05 |
| Earnings Date | Apr 30, 2019 - May 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.00 |
- Zacks•7 days ago
Cardiovascular Systems Gains on Global Growth & Innovation
Cardiovascular Systems (CSII) hopes that new product menu will deliver minimum 10% growth in its core business during the second half of fiscal 2019.
- Simply Wall St.•10 days ago
How Much is Cardiovascular Systems, Inc.’s (NASDAQ:CSII) CEO Getting Paid?
Scott Ward became the CEO of Cardiovascular Systems, Inc. (NASDAQ:CSII) in 2016. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we'll consider growth thatRead More...
- Business Wire•16 days ago
Cardiovascular Systems, Inc. to Present at Three Upcoming Investor Conferences
Cardiovascular Systems, Inc. , a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral
- PR Newswire•19 days ago
Washington Real Estate Investment Trust and Cardiovascular Systems Set to Join S&P SmallCap 600
NEW YORK , March 1, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600: Washington Real Estate Investment Trust (NYSE: WRE) will replace Investment Technology ...
- Zacks•21 days ago
Merit Medical (MMSI) Q4 Earnings & Revenues Surpass Estimates
Merit Medical (MMSI) registers solid expansion in adjusted gross margins in fourth-quarter 2018.
- Zacks•22 days ago
Veeva Systems (VEEV) Beats on Q4 Earnings and Revenues
Veeva Systems (VEEV) continues benefiting from its flagship Vault platform in fourth-quarter fiscal 2019.
- Zacks•22 days ago
Wright Medical (WMGI) Q4 Earnings & Revenues Beat Estimates
Wright Medical's (WMGI) top-line growth in fourth-quarter 2018 can be attributed to solid performance by the Upper and the Lower Extremities segments.
- Zacks•22 days ago
Bruker Rides on Robust NANO & CALID Groups, Recent Buyouts
Bruker's (BRKR) CALID and NANO groups hold promise.
- Zacks•22 days ago
Here's Why Investors Should Buy DexCom (DXCM) Stock Now
Solid growth at the Sensor, Transmitter and Receiver segments provide DexCom (DXCM) a competitive edge in the MedTech space.
- Zacks•24 days ago
CVS Health Rides on Aetna Synergy, PBM Selling Season Modest
With regard to its 2019 PBM selling season, CVS Health (CVS) notes that the net benefits from this selling season are expected to be modest on Anthem-related headwinds.
- Zacks•27 days ago
Here's Why Investors Should Hold DaVita (DVA) Stock Now
DaVita (DVA) steadily expands in international markets. Moreover, the company has witnessed Dialysis services in the United States lately.
- Zacks•28 days ago
Medidata's (MDSO) Margins Under Pressure, Competition Rife
Medidata (MDSO) suffers from cutthroat competition in the clinical trial solutions market at the moment.
- Business Wire•29 days ago
Cardiovascular Systems, Inc. to Present at the 8th Annual SVB Leerink Global Healthcare Conference
On Wednesday, February 27, 2019, Cardiovascular Systems’ Chairman, President and Chief Executive Officer, Scott Ward, and Chief Operating Officer, Rhonda Robb, will present at the 8th Annual SVB Leerink Global Healthcare Conference at 3:00 p.m.
- Zacks•last month
Here's Why Investors Should Buy Surmodics (SRDX) Stock Now
Surmodics' (SRDX) solid efforts to improve its research and development stature are likely to prove beneficial in the quarters ahead.
- GlobeNewswire•last month
New Research: Key Drivers of Growth for Omega Healthcare Investors, Cinedigm, Cardiovascular, Allegiant Travel, Catalyst Biosciences, and ESCO Technologies — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•last month
Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock
Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.
- Zacks•last month
Baxter's Acute Therapies Profile Strong, Competition Rife
Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.
- Zacks•last month
Here's Why Investors Should Retain AmerisourceBergen Stock
AmerisourceBergen (ABC) expects to witness solid growth at the Pharmaceutical Distribution segment in the long term.
- Zacks•last month
Here's Why You Should Buy Wright Medical (WMGI) Stock Now
A growing orthopedic market and strong international expansion make Wright Medical (WMGI) a promising investment pick at the moment.
- Zacks•last month
Here's Why You Should Invest in McKesson (MCK) Stock Now
McKesson's (MCK) solid prospects in the pharmaceutical and medical supplies distribution market look promising.
- Zacks•last month
Here's Why You Should Hold Intuitive Surgical (ISRG) Stock
Intuitive Surgical's (ISRG) solid exposure to robotics & medical mechatronics is commendable. Its robot-based da Vinci Surgical System for minimally-invasive surgery is an added positive.
- Thomson Reuters StreetEvents•last month
Edited Transcript of CSII earnings conference call or presentation 30-Jan-19 9:30pm GMT
Q2 2019 Cardiovascular Systems Inc Earnings Call
- Zacks•2 months ago
Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Meet
Cardiovascular Systems (CSII) benefits from year-over-year growth in both Coronary and peripheral device segments.
- Zacks•2 months ago
Cardiovascular Systems (CSII) Surpasses Q2 Earnings and Revenue Estimates
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 125.00% and 0.92%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
